Description
Tremelimumab ELISA Kit
The Tremelimumab ELISA Kit (SKU: GXEL00146) enables sensitive, reproducible quantitative detection of Tremelimumab in Plasma, Serum using a quantitative ELISA format. The assay delivers a detection range of 0.31-5 μg/mL and a sensitivity of 0.156 μg/ml and is read colorimetrically at 450 nm, making it well suited to quantitative research workflows.
Tremelimumab (CP-675, 206; previously, ticilimumab) is a fully human IgG2 monoclonal antibody and has a half-life of 22 days, which was generated in a XenoMouse murine system, that has a subnanomolar affinity for binding to human cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) for treatment of patients with advanced cancers. Treatment with an anti-CTLA4 mAb prevents normal downregulation of T cells and prolongs T cell activation, thereby enhancing immune function. Generated at Abgenix (Fremont, CA) using xenomice by Pfizer, Inc. (New York), tremelimumab has been undergoing human trials for the treatment of malignant melanoma. Additionally, tremelimumab is under investigation for the treatment of Mesothelioma, Liver Cancer, Liver Neoplasms, Liver Cell Caricinoma, and HepatoCellular Carcinoma and it has been investigated in Part C: Malignant Mesothelioma and Part A and B: Advanced Solid Malignancies. Recently, it has been announced by AstraZeneca and MedImmune that tremelimumab as monotherapy does not improve survival and the primary end point is not reached (D4880C00003; NCT01843374). Further data regarding DETERMINE was presented at ASCO 2016, detailing that 571 patients were enrolled and that 81% had died throughout the duration of the study. There was no statistically significant difference between treated patients and placebo patients, and side effects such as diarrhoea, loss of appetite and development of rashes were seen at higher rates in treated patients than in placebo treatments. This indicates a need for further research into the use of tremelimumab as a monotherapy as well as use in combination therapy to potentially achieve better clinical outcomes.
Supplied with pre-coated microplates and all core reagents, the Tremelimumab ELISA Kit gives you a validated, ready-to-use solution for Tremelimumab research. Get accurate and reliable results with the Tremelimumab ELISA Kit from Assay Genie.
| Product Name: | Tremelimumab ELISA Kit |
| SKU: | GXEL00146 |
| Accession: | P16410 |
| Alternative Names: | Ticilimumab, CP-675, CP-675, 206, CP-675206 clone 11.2.1, 745013-59-6 |
| Assay Type: | Quantitative |
| Detection Method: | Colorimetric |
| Sensitivity: | 0.156 μg/ml |
| Range: | 0.31-5 μg/mL |
| Sample Type: | Plasma, Serum |
| Storage: | 2-8°C. See Storage & Stability for details. |
| Note: | For Research Use Only. Not for diagnostic procedures. |
| Parameter | Specification |
|---|---|
| Assay Type | Quantitative |
| Detection Method | Colorimetric |
| Sensitivity | 0.156 μg/ml |
| Detection Range | 0.31-5 μg/mL |
| Recovery | 80-120% |
| Sample Types | Plasma, Serum |
The stability of ELISA kit is determined by the loss rate of activity. The loss rate of this kit is less than 10% prior to the expiration date under appropriate storage condition.
Store the kit at 2-8°C on receipt. Avoid repeated freeze-thaw cycles.
